Type II IFN (IFNγ) treatment can cause cell cycle arrest and inhibit the growth of pancreatic cancer cells by triggering caspase-1- and IRF1-dependent apoptosis (Detjen et al., 2001). Here, IRF1 is linked to familial pancreatic carcinoma.